73 Search Results

q=Prostate

Search Again


Geoffrey Baird , MD, PhD

Email: gbaird@uw.edu

Phone: (206)744-9787

Dr. Baird's clinical interests include laboratory test utilization, molecular diagnostics, proteomics and immunohistochemistry. His group has developed a new proteomic technology for biomarker discovery in a range of diseases such as malignancies, cardiovascular disorders, and inflammatory conditions. One application of their technology is to discover protein expression changes associated with non-small cell lung cancer that have implications for diagnosis and treatment.

View Bio

Laura Mae Baldwin , MD, MPH

Email: lmb@u.washington.edu

Phone: (206) 685-4799

Dr. Baldwin is a health services researcher with a focus on access to and quality of health care in diverse underserved and rural areas. Her areas of interest are cancer prevention and treatment, and perinatal health, all with an eye towards ensuring equitable access to high quality health services across U.S.

View Bio

Anirban Basu , PhD, MS

Email: basua@uw.edu

Phone: (206) 616-2986

Dr. Basu is a health economist whose research focuses on evaluations of treatments that can be personalized to generate value in health care settings. His research spans the areas of quality of life; with substantive focus on cancer and mental health. He has also worked on the theoretical and empirical foundations in cost-effectiveness analyses and value of information analyses in the context of prostate cancer and schizophrenia.

View Bio

Jason Bielas , PhD

Email: jbielas@fredhutch.org

Dr. Bielas leads a group group studies the fundamental and clinical implications of nuclear and mitochondrial DNA mutations in the pathogenesis of cancer and age-related disease including breast and ovarian cancer. Recently, his laboratory has developed a new test for predicting ovarian cancer survival.

View Bio

Lynn Bonham , PhD

Email: lbonham@seattlecca.org

Phone: (206)288-2022

Dr. Bonham directs and manages Cellular Therapeutics at SCCA, which processes cells from peripheral blood, bone marrow and cord blood for standard transplantations and clinical trials for cancer treatment.

View Bio

Robert Bradley , PhD

Email: rbradley@fredhutch.org

Phone: (206) 667-5662

Dr. Bradley uses genomics, sequence analysis, and molecular genetics to study the mechanistic origins and phenotypic consequences of alternative splicing and other RNA processing. He wants to identify diseases where RNA processing plays important, and previously unrecognized, roles. His laboratory studies pre-neoplastic diseases and cancers such as brain, prostrate and breast cancer.

View Bio

William Bremner , MD, PhD

Email: wbremner@u.washington.edu

Phone: (206) 543-3293

Dr. Bremner is an endocrinologist with expertise in the effects of testosterone and other androgens, especially in aging men. Dr. Bremner researches the effects of androgens and their metabolites on the body and the development of male contraceptives.

View Bio

Roger Brent , PhD

Email: rbrent@fredhutch.org

Phone: (206) 667-1482

Dr. Brent studies the quantitative operation of the systems that living cells use to sense, represent, transmit, and act upon information to make decisions that determine their future fates. He specifically studies prototypic cell signaling systems in budding yeast and the pheromone response system; he has extended similar work to systems operating in single cells of tissues in a metazoan, Caenorhabditis elegans.

View Bio

James (Jim) Brinkley , MD, PhD

Email: brinkley@u.washington.edu

Phone: (206) 543-3954

Dr. Brinkley's primary research interest is biomedical informatics - the representation, management, sharing, visualization and utilization of neuroscience data and knowledge. He is the founder of the field of Structural Informatics, which has as its goal the development of methods for representing the structure of the body at multiple levels of detail, as for using these methods for organizing and integrating biomedical information. His aim is to find ways to represent the structure or the body in computer-readable form, and find ways to associate these representations with the myriad biomedical data that are available. His goal is to provide a structural information framework for integrating a huge variety of big and small biomedical data. Dr. Brinkley's projects have included anatomy education, brain mapping through the national Human Brain Project, cardiovascular data integration, clinical trials data integration through the national Clinical translational Science Awards, radiological image annotation and integration through the RadLex project, and craniofacial malformations data integration through the national FaceBase consortium. He is also interested in developing web-accessible computer applications utilizing these representations to solve practical problems in clinical medicine, research and education.

View Bio

Mac Cheever , MD

Email: mcheever@fredhutch.org

Phone: (206) 667-4141

Dr. Cheever's specialty is in the areas of medical oncology, immunotherapy and solid tumor research. His current research interests are in conducting cancer clinical trials to develop and test new immunotherapies. He also interested on developing the principles of T cell therapy, cancer antigen discovery and development of cancer vaccines, especially for breast cancer.

View Bio

Chu Chen , PhD, NRCC, DABCC

Email: cchen@fredhutch.org

Phone: (206) 667-6644

Dr. Chen's research interests include the identification of 1) diagnostic and prognostic markers to aid personalized management of head and neck cancer based on gene expression profiles, loss of heterozygosity, DNA copy number, and tissue microarray data.; and 2) determinants for the susceptibility to and survival from cancers of the head and neck, lung, endometrium, breast, prostate and testes through investigations into lifestyle factors, endogenous and environmental exposures, and genetic and epigenetic influences.

View Bio

Heather Cheng , MD, PhD

Email: hhcheng@u.washington.edu

Phone: (206) 650-2205

Dr. Cheng cares for patients with prostate, bladder, and testicular cancers. Dr. Cheng's research interests include studying new treatments for prostate and bladder cancer through clinical trials, and understanding how to sequence the new drugs to maximize therapeutic benefit for patients. She is also studying blood-based cancer biomarkers, such as microRNAs.

View Bio

James Dai , PhD

Email: jdai@fredhutch.org

Phone: (206) 667-6364

James Dai’s Lab works in statistical genetics and genomics, design and analysis of randomized clinical trials, statistical methods for high-dimensional feature selection and prediction, gene-treatment interaction, mediation and instrumental variables regression. Methodologically, his lab is also interested in cancer genomics topics, for example integrative genomic analyses and intra-tumor heterogeneity. The overarching scientific interest is to discover and validate and genomic markers that drive cancer etiology, predict cancer prognosis and treatment efficacy.

View Bio

Ruth Etzioni , PhD

Email: retzioni@fredhutch.org

Phone: (206) 667-6561

Dr. Etzioni's group focuses on innovative statistical and computer modeling to project the comparative outcomes of cancer control interventions in an effort to develop a deeper, more mechanistic understanding of cancer progression. A few of the recent projects include, interrogation of trends in prostate cancer in the US population to quantify the roles of treatment changes; to interpret the results of the large prostate cancer screening trials; to generate unique insights about prostate cancer natural history and over-diagnosis due to PSA screening.

View Bio

Min Fang , MD, PhD

Email: fangm@uw.edu

Phone: (206) 288-1390

Dr. Fang's research focus is on the genomics and combinatorial genetics/epigenetics of human neoplasia. She is combining classical genetic approaches of mapping, karyotyping, and functional genetics with new genomic tools including microarray, comparative genome hybridization, and next-generation sequencing, to identify genetic and epigenetic aberrations in cancer that may serve as actionable biomarkers for treatment decision making for individual patients.

View Bio

Petros Grivas , MD, PhD

Email: pgrivas@uw.edu

Dr. Petros Grivas is a medical oncologist at Seattle Cancer Care Alliance with expertise in genitourinary cancers such as bladder cancer, prostate cancer and testis cancer.

View Bio

Barry Gumbiner , PhD

Email: gumbiner@uw.edu

Phone: 206-884-5116

Dr. Gumbiner and his team study how cadherin cell adhesion molecules and associated catenin proteins control tumor development and progression. Cadherins and catenins play important roles in the morphogenesis, maintenance, and regeneration of tissues, and alterations in their functions are important in cancer. One major effort of the laboratory is to understand how cadherins signal into the cell to control growth and differentiation through regulation of both the Wnt-beta-catenin pathway and the Hippo signaling pathway; the latter inhibits cell proliferation and participates in organ size control. Cadherins mediate contact inhibition of growth by stimulating the Hippo pathway, while growth factors, such as EGF, inhibit the Hippo pathway. They are investigating how these modes of regulation of the Hippo pathway affect the development of different types of tumors. Another major effort of the laboratory is to understand how cadherin adhesive function at the cell surface is regulated to control tissue architecture and tumor cell invasion. Loss of E-cadherin expression associated with the epithelial-mesenchymal transition (EMT) is known to promote tumorigenesis and metastasis. However, many tumors and metastases retain E-cadherin expression, and they have found that instead it can be inactivated at the cell surface to cause the loss in function. They have generated a novel class of monoclonal antibodies that activate E-cadherin at the cell surface to restore its adhesive function, and are evaluating whether they reduce tumor invasion and metastasis in animal models. He and his team are also studying how catenins and cancer-associated mutations in E-cadherin affect its ability to switch to the active state and regulate tumor development. The mechanisms by which cadherins and catenins affect tumor growth are varied and complex and offer potential approaches for intervention.

View Bio

Michael Haffner , MD, PhD

Email: mhaffner@fredhutch.org

Dr. Haffner’s lab focuses on elucidating alterations of the cytoskeleton in solid tumors with a focus on prostate cancer. For instance, they have recently described a novel protein, named AIM1 that regulates cytoskeletal organization by binding to actin, a major component of the cytoskeleton. When AIM1 is present, the cells' scaffolding keeps it rigid and correct shape. When AIM1 is lost, cells can remodel their cytoskeleton more frequently, change their shape and become capable of invading and migrating to distant locations. Notably, AIM1 function is disrupted in many solid tumors and genomic alterations of AIM1 are associated with aggressive tumor growth. The goal of these studies is to understand the mechanisms that govern changes in cell architecture to explore such cancer specific changes for therapeutic targeting.

View Bio

Celestia Higano , MD

Email: thigano@u.washington.edu

Phone: (206) 288-1152

Dr. Higano is a medical oncologist who specializes in genitourinary oncology with a focus on prostate cancer. Her research interest include: New agents for treatment of prostate cancer; use of intermittent androgen deprivation therapy (ADT); the effect of ADT and intermittent ADT on cognition, bone density, lipids, testosterone recovery, time to develop castration resistance; the effect of exercise to attenuate the effects of ADT; new drug development and clinical design; immunotherapy for prostate cancer.

View Bio